Invensys is doing better during the recession than Goldman Sachs expected, prompting the broker to its rating on the engineer from 'neutral' to 'buy'.Broker comment also sent banking giant HSBC higher. Swiss outfit Credit Suisse upped the shares to 'outperform' from 'neutral'.There were also gains for the drug majors, again thanks to kind words from analysts, this time Morgan Stanley. GlaxoSmithKline goes up to 'equalweight'.Oil titans BP and Shell joined miners Vedanta Resources and BHP Billiton in decline as the impact of commodity price rises wore off.FTSE 100 - RisersInvensys (ISYS) 241.50p +5.46%Royal Bank of Scotland Group (RBS) 39.90p +5.28%Drax Group (DRX) 476.75p +3.92%Barclays (BARC) 298.75p +3.55%Antofagasta (ANTO) 701.50p +3.31%GlaxoSmithKline (GSK) 1,065.00p +3.20%HSBC Holdings (HSBA) 553.00p +3.17%ICAP (IAP) 448.50p +2.93%Inmarsat (ISAT) 536.50p +2.88%Hammerson (HMSO) 320.75p +2.80%FTSE 100 - FallersCarnival (CCL) 1,524.00p -2.12%Vedanta Resources (VED) 1,743.00p -1.53%British Airways (BAY) 143.40p -1.51%Standard Chartered (STAN) 1,200.00p -1.48%Royal Dutch Shell 'B' (RDSB) 1,702.00p -1.33%SABMiller (SAB) 1,271.00p -1.24%BP (BP.) 526.50p -1.22%Pearson (PSON) 617.00p -1.20%BHP Billiton (BLT) 1,518.00p -1.04%Autonomy Corporation (AU.) 1,441.00p -1.03%